Wall Street brokerages expect Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) to announce sales of $115.44 million for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Ionis Pharmaceuticals’ earnings. The highest sales estimate is $137.00 million and the lowest is $95.25 million. Ionis Pharmaceuticals posted sales of $160.35 million during the same quarter last year, which suggests a negative year over year growth rate of 28%. The company is scheduled to issue its next quarterly earnings results on Tuesday, February 27th.
On average, analysts expect that Ionis Pharmaceuticals will report full-year sales of $115.44 million for the current financial year, with estimates ranging from $390.57 million to $486.00 million. For the next fiscal year, analysts forecast that the business will report sales of $514.99 million per share, with estimates ranging from $370.33 million to $818.00 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Ionis Pharmaceuticals.
IONS has been the subject of a number of analyst reports. Needham & Company LLC restated a “buy” rating and set a $64.00 price objective on shares of Ionis Pharmaceuticals in a research report on Tuesday, October 17th. Jefferies Group reiterated an “underperform” rating and set a $18.00 price target (up from $17.00) on shares of Ionis Pharmaceuticals in a report on Thursday, August 10th. Laidlaw reiterated a “buy” rating and set a $65.00 price target on shares of Ionis Pharmaceuticals in a report on Monday, August 14th. BMO Capital Markets lifted their price target on Ionis Pharmaceuticals from $67.00 to $69.00 and gave the stock an “outperform” rating in a report on Monday, August 14th. Finally, Stifel Nicolaus upped their price objective on Ionis Pharmaceuticals from $42.00 to $50.00 and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Three analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the stock. Ionis Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $50.31.
Large investors have recently modified their holdings of the business. Steward Partners Investment Advisory LLC acquired a new stake in shares of Ionis Pharmaceuticals in the 3rd quarter worth about $100,000. Parallel Advisors LLC lifted its position in shares of Ionis Pharmaceuticals by 62.8% in the second quarter. Parallel Advisors LLC now owns 2,073 shares of the company’s stock worth $109,000 after purchasing an additional 800 shares in the last quarter. Hanseatic Management Services Inc. raised its position in Ionis Pharmaceuticals by 1.2% during the second quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock valued at $177,000 after acquiring an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Ionis Pharmaceuticals by 9.1% in the second quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock valued at $190,000 after purchasing an additional 311 shares during the period. Finally, WFG Advisors LP boosted its stake in Ionis Pharmaceuticals by 77.2% during the second quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after buying an additional 1,655 shares in the last quarter. 91.58% of the stock is currently owned by institutional investors.
Shares of Ionis Pharmaceuticals (NASDAQ IONS) opened at $55.49 on Friday. The stock has a market cap of $6,605.43, a price-to-earnings ratio of 352.87 and a beta of 2.90. Ionis Pharmaceuticals has a twelve month low of $37.26 and a twelve month high of $65.51. The company has a quick ratio of 6.21, a current ratio of 6.25 and a debt-to-equity ratio of 1.50.
ILLEGAL ACTIVITY WARNING: This news story was first reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US and international trademark & copyright law. The correct version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/01/zacks-analysts-anticipate-ionis-pharmaceuticals-inc-ions-will-post-quarterly-sales-of-115-44-million.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.